Parabilis Medicines

Parabilis Medicines, formerly known as Fog Pharmaceuticals, is a clinical-stage biopharmaceutical company dedicated to creating drugs that can potentially bring life-changing impacts to people and patients by overcoming the limitations of existing options. The primary components adopted in Parabilis Medicines' Helicon™ therapy are α-helix-locked peptides, mainly composed of customized non-canonical amino acids. These "macromolecule small molecules" represent a new form of drug modality requiring an entirely new set of R&D capabilities. Helicon therapy combines the advantages of small molecule drugs and monoclonal antibodies. Like small molecule drugs, they exhibit cell permeability and broad tissue distribution. Similar to antibodies, Helicon demonstrates high specificity, the ability to block large molecular interactions between macromolecules, and the capacity to bind relatively flat surfaces. Helicon can be used to target multiple indications across various diseases.